Bellicum boosted on beta thalassemia update; Almac creates 180 new jobs;

@FierceBiotech: ICYMI yesterday: Agios slips on mixed solid tumor data for its Celgene-partnered cancer drug. More | Follow @FierceBiotech

@JohnCFierce: Old ACT was always reliable. Every fresh bit of data was a revolutionary breakthrough. But never got out of early stage R&D. | Follow @JohnCFierce

@DamianFierce: "I can't believe the future is sending feces around the country," said $MCBM's CEO, having never heard of Twitter. More from the NYT | Follow @DamianFierce

> Shares of Bellicum Pharmaceuticals ($BLCM) got an after-market boost Monday evening after the biotech noted that all four of the children suffering from beta thalassemia major were blood-transfusion independent within two weeks of being treated with BPX-501 engineered T cells. Release

> Almac is creating 180 new jobs at an old facility in Northern Ireland that once belonged to AstraZeneca. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: Google Life Sciences teams with AHA to target heart disease in $50M research initiative. Article | Follow @FierceMedDev

@VarunSaxena2: JAMA study: Rate of inappropriate stenting is declining. Story | Follow @VarunSaxena2

@EmilyWFierce: Scientists make strides toward full-body PET scanner with $15.5M in tow. Article | Follow @EmilyWFierce

> IBM brings Watson to Boston Children's Hospital for rare pediatric disease diagnosis. News

> FDA cracks down on genetic test makers for direct-to-consumer marketing. Report

Pharma News

@FiercePharma: Luye's schizophrenia drug gets nod to move ahead with NDA approval. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: | Follow @EricPFierce

@CarlyHFierce: $VRX "working hard" to reach out to payers, CEO says. "Historically, I have not spent a lot of time doing that." | Follow @CarlyHFierce

> Short-seller Citron spotlights Mallinckrodt as 'worse offender' than Valeant. Report

> J&J slapped with $1.8M verdict in Risperdal breast growth case. Article

Drug Delivery News

> Injectable HIV regimen being developed by J&J and ViiV Healthcare shows promise in trials. Report

> Canadian doctor opens blood-brain barrier using focused ultrasound. Item

> Ebola study will monitor viral entry into cells, with focus on drug delivery. Story

> Injectable HIV regimen being developed by J&J and ViiV Healthcare shows promise in trials. Article

> GSK beats AstraZeneca to finish line, wins FDA approval of first anti-IL-5 injectable for asthma. More

Pharma Manufacturing News

> Court orders Dr. Reddy's to temporarily halt sales of its purple Nexium copy. Story

> Pfizer recalls 21,000 bottles of Xanax that may be too weak. More

> Almac expanding in U.K., investing $24M in Charnwood tech park. Report

> Dr. Reddy's gets slapped with FDA warning letter for three Indian plants. Article

> Sun's U.S. sales crater as plant issues cut deeply. Story

Pharma Asia News

> AstraZeneca shows more solid gains in China on respiratory. More

> Luye's schizophrenia drug gets nod to move ahead with NDA approval. Story

> China to restart mainland IPOs, with pharma ready to roll. Item

> FDA widens review of Dr. Reddy's manufacturing ops. More

> India's Sun Pharmaceutical takes another Ranbaxy-related hit. Article

Suggested Articles

Minerva's seltorexant helped patients fall asleep more quickly and stay asleep for longer, beating placebo and Sanofi’s Ambien in a phase 2b study.

Cannabidiol might work as a powerful antibiotic against certain drug-resistant bacteria such as methicillin-resistant S. aureus.

Krystal Biotech posted data from a phase 2 study showing its topical gene therapy closed the majority of wounds in patients with a rare skin disorder.